Global Dermatophytic Onychomycosis Market Research Report 2022

Market Analysis and Insights: Global Dermatophytic Onychomycosis Market
Dermatophytic onychomycosis is a fungal infection of the nail plate, nail bed, and, in some cases, the skin surrounding the nail plate. It is caused by yeast, dermatophytes, and molds; dermatophytes account for 90% of all cases. The fungus, especially Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, infects the skin, hair, or nails. It is often perceived by people to be an active and contagious infection. Onychomycosis may persist or worsen if not treated. The fungi that cause onychomycosis exist in common sites such as floors, soil, socks, and shoes. Therapies for onychomycosis include debridement and drugs. Debridement is time consuming and minimally effective in eradicating the fungal infection. Systemic drug treatment is most effective in treating onychomycosis.
The global Dermatophytic Onychomycosis market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Factors such as the rising prevalence of dermatophytic onychomycosis, heavy investments to develop therapies, and frequent product innovations will aid in the steady growth of this market during the forecast period. An important factor that will impel the prospects for growth in this market is the augmented focus on combination therapies. Recently, it has been observed that a combination of topical and systemic treatment increases the cure rate when compared to individual therapies. Since combination therapies have improved clinical efficiency and are more cost-effective than terbinafine, they are increasingly being preferred over individual terbinafine-based therapies as they have a higher cure rate.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Dermatophytic Onychomycosis market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Dermatophytic Onychomycosis market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Dermatophytic Onychomycosis market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Dermatophytic Onychomycosis market.
Global Dermatophytic Onychomycosis Scope and Market Size
Dermatophytic Onychomycosis market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Dermatophytic Onychomycosis market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.

Segment by Type
Oral Medicine
External Medicine

Segment by Application
Age Under 18
Age 18-50
Age Above 50

By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Johnson & Johnson
GSK
Novartis
Pfizer
Bausch Health
Kaken Pharmaceutical
Galderma
Sanofi
Allergan
Merz Pharma
Xiuzheng Pharmaceutical
Letai
Qilu Pharmaceutical